Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 24/11/2015 The researchers from Tübingen were able to decipher in detail the site where the JC polyomavirus binds to the host cell. The yellow molecule structure shows the sugar residues on the surface of the host cell encased in the binding pocket of the viral protein.

    Researchers from Tübingen set out to thwart viral survival strategies

    Around two thirds of people carry the JC polyomavirus, a normally harmless virus that, in immunocompromised patients, can evade the body’s defences and cause a fatal brain infection. An international research network has now found a way to activate the immune system and attack the virus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/researchers-from-tuebingen-set-out-to-thwart-viral-survival-strategies
  • Press release - 03/11/2015 07777_de.jpg

    CureVac raises $110 Million in a private placement

    CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
  • Article - 11/05/2015 B/w electron microscope image of a Lactobacillus rhamnosus bacterium that is in contact with a keratinocyte (measuring bar = 0.1).

    How Lactobacillus bacteria fight Candida albicans infections

    Fungal infections of skin and mucous membranes are relatively common. Around 75 percent of the human population lives with Candida albicans, a fungus that has no harmful effects in people with an intact immune system that can fight off systemic infections. However, in people with immune systems that have been weakened by antibiotics or radiotherapy for example C. albicans infections can lead to sepsis which may even be life-threatening. Prof. Dr.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-lactobacillus-bacteria-fight-candida-albicans-infections
  • Article - 09/03/2015 22905_de.jpg

    Treating cancer by activating the immune system

    Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/treating-cancer-by-activating-the-immune-system
  • Press release - 06/03/2015 07777_de.jpg

    The Bill & Melinda Gates Foundation invests €46 million in CureVac

    The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest €46 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA platform. In addition, CureVac’s…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-bill-melinda-gates-foundation-invests-46-million-in-curevac
  • Article - 26/01/2015 Photo showing a laboratory involved in the TTU "Malaria". The photo shows two scientists working at a work bench.

    Pooling efforts against infectious diseases in Germany

    Over 150 scientists at various locations throughout Germany work together as part of the German Centre for Infection Research (DZIF). The centre focuses on the development of new diagnostic, preventive and therapeutic methods for treating infectious diseases. Scientists from the University and University Hospital of Tübingen and the Max Planck Institute for Developmental Biology are also part of the project. The researchers from Tübingen are…

    https://www.gesundheitsindustrie-bw.de/en/article/news/pooling-efforts-against-infectious-diseases-in-germany
  • Article - 22/12/2014 22598_de.jpg

    Fighting hepatitis viruses with their own weapons

    Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…

    https://www.gesundheitsindustrie-bw.de/en/article/news/fighting-hepatitis-viruses-with-their-own-weapons
  • Press release - 26/11/2014 15740_de.jpg

    Curetis Closes EUR 14.5 Million Extension of Series B Financing

    Curetis AG wins new investors QIAGEN and LSP-HEF, committing EUR 7 million. Hence Curetis is well financed into 2017. Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-closes-eur-14-5-million-extension-of-series-b-financing
  • Article - 24/11/2014 Three-dimensional microscopic representation of a synthetic vesicle that is invaded by bacteria.

    Lipid zipper triggers bacterial invasion

    Millions of people die each year from infections both in developing and industrial countries. There is still no effective treatment for a large number of diseases caused by pathogens. In order to treat infectious diseases effectively, we need to understand the mechanisms that bacteria use to infect human cells. The cytoskeleton of the host cell usually plays a key role in this process. Researchers at the University of Freiburg have discovered a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/lipid-zipper-triggers-bacterial-invasion
  • Article - 20/10/2014 22216_de.jpg

    Michael Schindler: HI virus and host interactions

    Prof. Dr. Michael Schindler explores the interaction between viruses and their human host cells on the molecular level. His specific interest is HI virus infections and the mechanisms the virus uses to attack the human immune system. Schindler’s eventual aim is to identify a new target for the therapy of HIV infections. In April 2014, Schindler was appointed head of the Department of Molecular Virology of Human Infectious Diseases at the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/michael-schindler-hi-virus-and-host-interactions
  • Article - 30/06/2014 21541_de.jpg

    The German National Cohort: collecting data for a healthier future

    A large-scale long-term cohort study will be carried out to explain the causes of widespread diseases, in particular cancer, coronary heart disease, stroke and diabetes, and to identify the risk factors that lead to or favour the development of a certain disease. The principal objective of the German National Cohort (GNC) is to create the conditions that enable the development of new strategies for the prevention, risk assessment and early…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-german-national-cohort-collecting-data-for-a-healthier-future
  • Article - 12/05/2014 21187_de.jpg

    A DNA cracker from Ulm for making clean drinking water

    Drinking water that is pathogen-free and safe for humans flows from German taps. There is no nutrient as vital to human beings as water and – at least in Germany – that is subjected to so many checks and controls. Nevertheless, access to clean drinking water is not to be taken as given. According to the latest WHO figures (2011), 768 million people do not have access to healthy drinking water, especially in some of the poorer African countries.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-dna-cracker-from-ulm-for-making-clean-drinking-water
  • Article - 28/04/2014 Co-existence mechanism of gram-positive staphylococci and gram-negative bacteria Gram-negative bacteria. (S. marcescens, P. aeruginosa, V. harveyi und C. subtsugae). The staphylococci secrete two compounds (Yayurea A and B) that inhibit the growth and chemical communication of gram-negative bacteria. Yayurea A and B are represented by their structural formula. The gram-negative bacteria are no longer able to produce compounds such as prodigiosin, pyocyanin, bioluminescence compounds and violacein.<br /> <br />

    New ways to interfere with bacterial strategies

    Bacteria themselves provide the key to their destruction. New insights into the growth and interaction between different pathogens are used in microbial genetics to develop new methods and active substances for combatting multidrug-resistant bacterial strains.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-ways-to-interfere-with-bacterial-strategies
  • Dossier - 28/04/2014 Researcher sitting in front of two screens, visualising a protein on the screen using a specific software.<br />

    Data mining: new opportunities for medicine and public health

    Research and healthcare activities produce huge quantities of data that need to be presented in an understandable structure. This requires computer-assisted extraction of relevant data and the use of statistical methods. This process, known as data mining, enables the discovery of patterns in large data sets. Data mining methods are of particular importance in fields that use high-throughput methods, visualisation methods and telemedical…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/data-mining-new-opportunities-for-medicine-and-public-health
  • Article - 31/03/2014 21168_de.jpg

    The growing significance of peptide therapeutics

    The therapeutic use of peptides lags behind that of proteins. And there are good reasons for this. However, it seems that this is beginning to change and that peptide therapeutics are growing in significance. As a matter of fact, peptides have become rather popular candidates for drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-growing-significance-of-peptide-therapeutics
  • Dossier - 10/02/2014 Electron microscope image of Staphylococcus aureus bacteria which have become resistant to many antibiotics.

    Multiresistant pathogens – a self-inflicted threat?

    Most bacterial infections have lost their capacity to cause terror thanks to antibiotics. However, the increase in antibiotic resistances is making the fight against bacterial pathogens rather difficult, and the widespread overuse and inappropriate use of antibiotics continues to fuel the increase in antibiotic-resistant bacteria. Strict surveillance strategies and hygiene rules have been in place for some years with the aim of ensuring the…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/multiresistant-pathogens-a-self-inflicted-threat
  • Article - 25/01/2014 20891_de.jpg

    Call for responsible antibiotics prescription

    Heidelberg University Hospital and the University Medical Centre in Mannheim are working hard to counteract the increase of antibiotic resistance. Strategies include a European-wide system for infection surveillance, the training of health professionals in the responsible use of antibiotics and the search for novel antibiotic substances in unconventional organisms.

    https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-responsible-antibiotics-prescription
  • Article - 20/01/2014 20602_de.jpg

    Curetis AG: Miniaturised laboratory for the simple, rapid and reliable diagnosis of serious infections

    Acute pneumonia usually leaves doctors with no choice the situation can quickly become life threatening requiring doctors to act quickly. Instead of waiting for laboratory results they often prescribe an antibiotic that is effective against numerous bacterial species in the hope that it will also work against the bacterium that has caused the inflammation in the lung tissue. Curetis AG from Holzgerlingen close to Stuttgart has developed a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curetis-ag-miniaturised-laboratory-for-the-simple-rapid-and-reliable-diagnosis-of-serious-infections
  • Article - 13/01/2014 The photo shows vials with caps, arranged in two rows.

    DIARECT AG – development and production of immunodiagnostics components

    Founded by Dr. Heinz Haubruck and Prof. Dr. Bodo Liedvogel in 1998, the biotechnology company DIARECT AG (DIAgnostic by RECombinant Technology) from Freiburg sells tried and tested and new products. The company produces proteins, nucleoproteins and assay components for the diagnostics sector. These products enable the reliable identification of autoimmune disorders and infectious diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/diarect-ag-development-and-production-of-immunodiagnostics-components
  • Article - 29/11/2013 20630_de.jpg

    QIAGEN Lake Constance: a “disk player” for rapid diagnoses

    The diagnosis of infectious diseases frequently not only depends on the reliable identification of the pathogenic species that has caused them, but also on obtaining rapid results in order to immediately initiate appropriate therapy or further diagnostic measures. Tests are normally carried out in central laboratories, samples need to be sent to the laboratories and the results are rarely immediate. As part of the BMBF-funded project “ResCheck”,…

    https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-a-disk-player-for-rapid-diagnoses
  • Article - 31/10/2013 Fruit mummy, a small, unripe, dried-up fruit of the previous year, on an apple tree.

    Fire blight monitoring generates new knowledge

    Plant diseases such as fire blight, a common infectious disease that predominantly affects pomaceous fruit trees, can reach epidemic proportions. Weather-based prediction models, which are routinely used to calculate fire blight infection risk, can now be replaced by a molecular test that is far more accurate. This new test is used by Bio-Protect GmbH and Büro für Biologische-Ökologische Beratung, both located in Konstanz and members of BioLAGO,…

    https://www.gesundheitsindustrie-bw.de/en/article/news/fire-blight-monitoring-generates-new-knowledge
  • Article - 30/09/2013 Person holding a vial with vaccine.

    CureVac GmbH: RNA-based vaccines and immunotherapies

    CureVac GmbH, a biopharmaceutical company based in Tübingen, develops immunotherapies for cancer along with prophylactic vaccines based on its proprietary messenger RNA (mRNA) technology platform. CureVac also uses RNA for developing adjuvants. Two clinical trials, a Phase I trial in non-small cell lung cancer (NSCLC) and a Phase IIb trial in prostate cancer, are currently underway to test the efficiency of mRNA-based drugs in treating cancer and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-gmbh-rna-based-vaccines-and-immunotherapies
  • Article - 17/05/2013 19602_de.jpg

    Dengue fever, the neglected infectious disease

    Dengue fever is the most common infectious disease transmitted by mosquitoes. The disease is spreading in Europe and Germany, an upward trend that is due to increased long-distance travel. There are no specific drugs or vaccine for dengue, which is why an international research network has been established to improve the management of the disease. The consortium is coordinated by the Department of Tropical Medicine at Heidelberg University.

    https://www.gesundheitsindustrie-bw.de/en/article/news/dengue-fever-the-neglected-infectious-disease
  • Dossier - 13/05/2013 19501_de.jpg

    The human proteome – the next major goal

    The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
  • Article - 11/02/2013 19149_de.jpg

    Johannes Krause examines historical pathogens: old pathogens in a new light

    Palaeogeneticist Johannes Krause is drawn to ancient DNA. His work on the evolution of human pathogens shows that his findings are not purely of historical interest, but also enable conclusions to be made on future disease outbreaks and epidemics. In autumn 2012, Krause was awarded an ERC Starting Grant. Krause uses the grant to expand his research into plague and other historical pathogens that continue to be a threat to human health.

    https://www.gesundheitsindustrie-bw.de/en/article/news/johannes-krause-examines-historical-pathogens-old-pathogens-in-a-new-light

Page 4 / 7

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search